Estela Rodriguez, Associate Director of Community Outreach and Co-Lead of Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center, shared a post on X:
“Great Debates Miami
Still smiling after debating Dr. Luis E. Raez on IO monotherapy vs combination CTLA4/PDL1
Although I lost -due to a ‘sampling error’, -we both agreed that high-risk tumors, PDL1 neg, STK11, KEAP1, KRAS can benefit from CTLA4 therapy upfront).”
More from Estela Rodriguez on OncoDaily.
